Advancing Precision Medicine in NSCLC: Real-World Impact of the PREDICT Initiative

<p>A 2025 study in <i data-end="580" data-start="573">Chest</i> evaluated PREDICT, a precision medicine program at a large academic-community practice, designed to streamline testing and expand access to personalized treatment for non-small cell lung cancer (NSCLC). Hear from ReachMD's Ryan Quigley as he shares the key impacts of this approach and implications for care delivery.</p>